(Q37939200)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

review article

1 reference

title

An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Stephen J Clarke

6

1 reference

ORCID Public Data File 2021

author name string

Viet Hong Phan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Cindy Tan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Anneliese Rittau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Hongmei Xu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

28 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1395-1410

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Exploring differences in drug doses between Japan and Western countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology G

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Emerging ethnic differences in lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Predicting drug response and toxicity based on gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Functional characterization of cytochrome P450 2B6 allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

CYP450 pharmacogenetics for personalizing cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Safety of concomitant tamoxifen and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Antimycotic drug discovery in the age of genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Identification and functional characterization of eight CYP3A4 protein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Significance of the minor cytochrome P450 3A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

21 January 2018

Glutathione transferases

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

The 341C/T polymorphism in the GSTP1 gene is associated with increased risk of oesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

UGT genomic diversity: beyond gene duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Glucuronidation of Etoposide in Human Liver Microsomes Is Specifically Catalyzed by UDP-Glucuronosyltransferase 1A1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Genetic factors influencing pyrimidine-antagonist chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.624513

10.1517/17425255.2011.624513

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21950349%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference